CCS in the treatment of NMSCs is expedient and well tolerated, with no major and few minor complications. When performed as in the present study it produces good cosmetic results in virtually all cases, with an anticipated 97% cure rate after 14 years. CCS is thus a highly viable alternative in the treatment of NMSCs in the face and on the scalp.

Estimates of the incremental cost-effectiveness ratio are far below the currently discussed threshold in Sweden, corresponding to approximately 48,700 British pound per QALY gained, and equivalent thresholds in other countries. Treatment with tacrolimus ointment in patients with moderate and severe AD can therefore be considered cost-effective.